In conclusion, serum IGF-1 and IL-6 can be used as biochemical indicators for diagnosing and judging the progression of DKD, which is closely related to the kidney damage of the disease, and the combination of the two can improve the sensitivity and specificity of the assay, which has guiding significance for the subsequent diagnosis and treatment of DKD. This evidence concerns the gene IL6 and diabetic kidney disease.